| 袁少华,顾 朋,王 薇,王培红,樊喜文.肝动脉化疗栓塞术联合碘125粒子植入对原发性肝癌合并门静脉癌栓患者血清TSGF、TK-1、sB7-H3水平的影响[J].,2023,(21):4071-4075 |
| 肝动脉化疗栓塞术联合碘125粒子植入对原发性肝癌合并门静脉癌栓患者血清TSGF、TK-1、sB7-H3水平的影响 |
| Efficacy of Transcatheter Arterial Chemoembolization Combined with Iodine 125 Seed Implantation in the Primary Hepatic Cancer Combined with Portal Vein Tumor Thrombus and Its Impact on Serum TSGF, TK-1, sB7-H3 |
| 投稿时间：2023-05-01 修订日期：2023-05-24 |
| DOI：10.13241/j.cnki.pmb.2023.21.013 |
| 中文关键词: 原发性肝癌合并门静脉癌栓 肝动脉化疗栓塞术 疗效 碘125粒子 恶性肿瘤特异性生长因子 胸苷激酶1 可溶性B7-H3 |
| 英文关键词: Primary hepatic cancer combined with portal vein tumor thrombus Transcatheter arterial chemoembolization Efficacy Iodine 125 seed Tumor specific growth factor Thymidine kinase 1 Soluble B7-H3 |
| 基金项目:新疆维吾尔自治区科技支疆项目计划（指令性）项目（2022E02048） |
|
| 摘要点击次数: 194 |
| 全文下载次数: 157 |
| 中文摘要: |
| 摘要 目的：观察肝动脉化疗栓塞术（TACE）联合碘125粒子植入治疗原发性肝癌（PHC）合并门静脉癌栓（PVTT）的疗效及对血清恶性肿瘤特异性生长因子（TSGF）、胸苷激酶1（TK-1）、可溶性B7-H3（sB7-H3）的影响。方法：选择新疆医科大学附属肿瘤医院2019年1月到2020年1月期间收治的PHC合并PVTT患者120例，按照随机数字表法分为对照组（TACE治疗，60例）和联合组（TACE结合碘125粒子植入治疗，60例）。观察两组疗效、肝功能指标[丙氨酸氨基转移酶（ALT）、谷草转氨酶（AST）、总胆红素（TBiL）]、血清肿瘤标志物[甲胎蛋白（AFP）、细胞角蛋白19片段（CYFRA21-1）及癌胚抗原（CEA）]、TSGF、TK-1、sB7-H3。随访3年，采用Kaplan-Meier曲线分析（Log-Rank检验）两组患者总生存期（OS）的差异。结果：联合组的临床总有效率高于对照组（P<0.05）。与治疗前相比，两组治疗后ALT、AST、TBiL均下降，且联合组均低于对照组同期（P<0.05）。与治疗前相比，两组治疗后AFP、CYFRA21-1、CEA均下降，且联合组均低于对照组同期（P<0.05）。与治疗前相比，两组治疗后TSGF、TK-1、sB7-H3均下降，且联合组均低于对照组同期（P<0.05）。联合组的OS长于对照组（P<0.05）。结论：TACE联合碘125粒子植入治疗PHC合并PVTT患者，可提高临床疗效，降低血清肿瘤标志物水平，减轻肝功能损伤，延长患者OS并调节血清TSGF、TK-1、sB7-H3水平。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of transcatheter arterial chemoembolization (TACE) combine with iodine 125 seed implantation in the treatment of primary hepatic cancer (PHC) combined with portal vein tumor thrombus (PVTT) and its impact on serum tumor specific growth factor (TSGF), thymidine kinase 1 (TK-1), and soluble B7-H3 (sB7-H3). Methods: 120 patients with PHC combined with PVTT who were admitted to the Cancer Hospital Affiliated to Xinjiang Medical University from January 2019 to January 2020 were selected. They were divided into control group (treated with TACE, 60 cases) and combined group (treated with TACE combined with iodine 125 seed implantation, 60 cases) according to the random number table method. The efficacy, hepatic function indexes [alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBiL)], serum tumor markers [alpha fetoprotein (AFP), cytokeratin-19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA)], TSGF, TK-1 and sB7-H3 were observed. Followed up for 3 years, the difference in overall survival time(OS) between two groups of patients was analyzed by Kaplan-Meier curve (Log-Rank test). Results: The total clinical effective rate in combined group was higher than that in control group(P<0.05). Compared with before treatment, ALT, AST and TBiL decreased in two groups after treatment, and those in combined group were lower than those in control group during the same period(P<0.05). Compared with before treatment, AFP, CYFRA21-1 and CEA decreased in two groups after treatment, and those in combined group were lower than those in control group during the same period(P<0.05). Compared with before treatment, TSGF, TK-1 and sB7-H3 decreased in two groups after treatment, and those in combined group were lower than those in control group during the same period (P<0.05). The OS in combined group was longer than that in control group (P<0.05). Conclusion: The TACE combined with iodine 125 seed implantation for the treatment of patients with PHC combine with PVTT, which can improve clinical efficacy, reduce serum tumor marker levels, reduce hepatic function damage, extend OS of patients and regulate serum TSGF, TK-1 and sB7-H3 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
